Ledipasvir / Sofosbuvir (Addendum to Commission A14-44) [Internet].

On 8 April 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A14-44 (Ledipasvir / sofosbuvir – Benefit assessment according to §35a Social Code Book (SGB) V).

http://ift.tt/2ryB0q5